Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner

Journal of Immunology

Volumn 181, Issue 4, 2008, Pages 2321-2329

  Mars, Lennart T ^a,b   Gautron, Anne Sophie ^c,d   Novak, Jan ^c,d   Beaudoin, Lucie ^c,d   Diana, Julien ^c,d   Liblau, Roland S ^a,b   Lehuen, Agnès ^c,d  

^a CHU PURPAN   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Hôpital Cochin/Saint Vincent de Paul ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 4; CD1 ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL STRESS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; EFFECTOR CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER T CELL; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH17 CELL; THYMUS; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL MOTION; COCULTURE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; NATURAL KILLER CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD1; CELL MOVEMENT; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTE SUBSETS;

EID: 53149111593     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.4.2321     Document Type: Article

References (66)

1. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
2. Zhou, D., J. Mattner, C. Cantu, III, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
3. Porubsky, S., A. O. Speak, B. Luckow, V. Cerundolo, F. M. Platt, and H. J. Grone. 2007. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. USA 104: 5977-5982.
4. Speak, A. O., M. Salio, D. C. Neville, J. Fontaine, D. A. Priestman, N. Platt, T. Heare, T. D. Butters, R. A. Dwek, F. Trottein, et al. 2007. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. USA 104: 5971-5976.
5. Matsuda, J. L., L. Gapin, S. Sidobre, W. C. Kieper, J. T. Tan, R. Ceredig, C. D. Surh, and M. Kronenberg. 2002. Homeostasis of Vα14i NKT cells. Nat. Immunol. 3: 966-974.
6. Wei, D. G., H. Lee, S. H. Park, L. Beaudoin, L. Teyton, A. Lehuen, and A. Bendelac. 2005. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J. Exp. Med. 202: 239-248.
7. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477.
8. Benlagha, K., and A. Bendelac. 2000. CD1d-restricted mouse Vα14 and human Vα24 T cells: lymphocytes of innate immunity. Semin. Immunol. 12: 537-542.
9. Benlagha, K., D. G. Wei, J. Veiga, L. Teyton, and A. Bendelac. 2005. Characterization of the early stages of thymic NKT cell development. J. Exp. Med. 202: 485-492.
10. + CD1d-dependent precursor stage. J. Exp. Med. 195: 835-844.
11. Benlagha, K., T. Kyin, A. Beavis, L. Teyton, and A. Bendelac. 2002. A thymic precursor to the NK T cell lineage. Science 296: 553-555.
12. McNab, F. W., S. P. Berzins, D. G. Pellicci, K. Kyparissoudis, K. Field, M. J. Smyth, and D. I. Godfrey. 2005. The influence of CD1d in postselection NKT cell maturation and homeostasis. J. Immunol. 175: 3762-3768.
13. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen, and J. P. Di Santo. 2003. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. USA 100: 2663-2668.
14. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
15. Mazzanti, B., M. Vergelli, P. Riccio, R. Martin, H. F. McFarland, G. M. Liuzzi, L. Amaducci, and L. Massacesi. 1998. T-cell response to myelin basic protein and lipid-bound myelin basic protein in patients with multiple sclerosis and healthy donors. J. Neuroimmunol. 82: 96-100.
16. Ilyas, A. A., Z. W. Chen, and S. D. Cook. 2003. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 139: 76-80.
17. Pender, M. P., P. A. Csurhes, N. P. Wolfe, K. D. Hooper, M. F. Good, P. A. McCombe, and J. M. Greer. 2003. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10: 63-66.
18. Uhlig, H., and R. Dernick. 1989. Monoclonal autoantibodies derived from multiple sclerosis patients and control persons and their reactivities with antigens of the central nervous system. Autoimmunity 5: 87-99.
19. Shamshiev, A., A. Donda, I. Carena, L. Mori, L. Kappos, and G. De Libero. 1999. Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 29: 1667-1675.
20. Sadatipour, B. T., J. M. Greer, and M. P. Pender. 1998. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 44: 980-983.
21. Kanter, J. L., S. Narayana, P. P. Ho, I. Catz, K. G. Warren, R. A. Sobel, L. Steinman, and W. H. Robinson. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12: 138-143.
22. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
23. Serafini, B., B. Rosicarelli, R. Magliozzi, E. Stigliano, E. Capello, G. L. Mancardi, and F. Aloisi. 2006. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 65: 124-141.
24. Hoftberger, R., F. Aboul-Enein, W. Brueck, C. Lucchinetti, M. Rodriguez, M. Schmidbauer, K. Jellinger, and H. Lassmann. 2004. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14: 43-50.
25. Battistini, L., F. R. Fischer, C. S. Raine, and C. F. Brosnan. 1996. CD1b is expressed in multiple sclerosis lesions. J. Neuroimmunol. 67: 145-151.
26. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100: 144-148.
27. Illes, Z., T. Kondo, J. Newcombe, N. Oka, T. Tabira, and T. Yamamura. 2000. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164: 4375-4381.
28. + NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15: 279-288.
29. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
30. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799.
31. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
32. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by αGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur. J. Immunol. 33: 1830-1838.
33. Mars, L. T., V. Laloux, K. Goude, S. Desbois, A. Saoudi, L. Van Kaer, H. Lassmann, A. Herbelin, A. Lehuen, and R. S. Liblau. 2002. Cutting edge: Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168: 6007-6011.
34. Mars, L. T., J. Novak, R. S. Liblau, and A. Lehuen. 2004. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol. 25: 471-476.
35. Lehuen, A., O. Lantz, L. Beaudoin, V. Laloux, C. Carnaud, A. Bendelac, J. F. Bach, and R. C. Monteiro. 1998. Overexpression of natural killer T cells protects Vα14- Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188: 1831-1839.
36. Allen, J. M., K. A. Forbush, and R. M. Perlmutter. 1992. Functional dissection of the lck proximal promoter. Mol. Cell. Biol. 12: 2758-2768.
37. Novak, J., L. Beaudoin, S. Park, T. Griseri, L. Teyton, A. Bendelac, and A. Lehuen. 2007. Prevention of type 1 diabetes by invariant NKT cells is independent of peripheral CD1d expression. J. Immunol. 178: 1332-1340.
38. Giulietti, A., L. Overbergh, D. Valckx, B. Decallonne, R. Bouillon, and C. Mathieu. 2001. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25: 386-401.
39. Halloran, P. F., J. Urmson, V. Ramassar, A. Melk, L. F. Zhu, B. P. Halloran, and R. C. Bleackley. 2004. Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and B. Am. J. Transplant. 4: 705-712.
40. Huang, M. C., S. R. Watson, J. J. Liao, and E. J. Goetzl. 2007. Th17 augmentation in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor double transgenic mice. J. Immunol. 178: 6806-6813.
41. Benlagha, K., A. Weiss, A. Beavis, L. Teyton, and A. Bendelac. 2000. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191: 1895-1903.
42. Busshoff, U., A. Hein, A. Iglesias, R. Dorries, and A. Regnier-Vigouroux. 2001. CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination. J. Neuroimmunol. 113: 220-230.
43. Galea, I., M. Bernardes-Silva, P. A. Forse, N. van Rooijen, R. S. Liblau, and V. H. Perry. 2007. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 204: 2023-2030.
44. Slavin, A. J., J. M. Soos, O. Stuve, J. C. Patarroyo, H. L. Weiner, A. Fontana, E. K. Bikoff, and S. S. Zamvil. 2001. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J. Clin. Invest. 108: 1133-1139.
45. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168: 4173-4183.
46. Greter, M., F. L. Heppner, M. P. Lemos, B. M. Odermatt, N. Goebels, T. Laufer, R. J. Noelle, and B. Becher. 2005. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11: 328-334.
47. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
48. Michel, M. L., A. C. Keller, C. Paget, M. Fujio, F. Trottein, P. B. Savage, C. H. Wong, E. Schneider, M. Dy, and M. C. Leite-de-Moraes. 2007. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204: 995-1001.
49. Beaudoin, L., V. Laloux, J. Novak, B. Lucas, and A. Lehuen. 2002. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17: 725-736.
50. Mempel, M., C. Ronet, F. Suarez, M. Gilleron, G. Puzo, L. Van Kaer, A. Lehuen, P. Kourilsky, and G. Gachelin. 2002. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J. Immunol. 168: 365-371.
51. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
52. Becher, B., B. G. Durell, and R. J. Noelle. 2003. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 112: 1186-1191.
53. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, et al. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA 95: 5690-5693.
54. Zhang, B., T. Yamamura, T. Kondo, M. Fujiwara, and T. Tabira. 1997. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186: 1677-1687.
55. Xu, W., G. Fazekas, H. Hara, and T. Tabira. 2005. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 163: 24-30.
56. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
57. Kinjo, Y., D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
58. Kinjo, Y., E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. R. Benhnia, D. M. Zajonc, G. Ben-Menachem, G. D. Ainge, G. F. Painter, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7: 978-986.
59. Galli, G., S. Nuti, S. Tavarini, L. Galli-Stampino, C. De Lalla, G. Casorati, P. Dellabona, and S. Abrignani. 2003. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197: 1051-1057.
60. Vincent, M. S., D. S. Leslie, J. E. Gumperz, X. Xiong, E. P. Grant, and M. B. Brenner. 2002. CD1-dependent dendritic cell instruction. Nat. Immunol. 3: 1163-1168.
61. Nagarajan, N. A., and M. Kronenberg. 2007. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 178: 2706-2713.
62. Leite-De-Moraes, M. C., A. Hameg, A. Arnould, F. Machavoine, Y. Koezuka, E. Schneider, A. Herbelin, and M. Dy. 1999. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J. Immunol. 163: 5871-5876.
63. Leite-De-Moraes, M. C., A. Hameg, M. Pacilio, Y. Koezuka, M. Taniguchi, L. Van Kaer, E. Schneider, M. Dy, and A. Herbelin. 2001. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J. Immunol. 166: 945-951.
64. Gigli, G., S. Caielli, D. Cutuli, and M. Falcone. 2007. Innate immunity modulates autoimmunity: type 1 interferon-β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 122: 409-417.
65. + T cells in vivo by IL-15. Immunity 8: 591-599.
66. Durbin, J. E., A. Fernandez-Sesma, C. K. Lee, T. D. Rao, A. B. Frey, T. M. Moran, S. Vukmanovic, A. Garcia-Sastre, and D. E. Levy. 2000. Type I IFN modulates innate and specific antiviral immunity. J. Immunol. 164: 4220-4228.